Oncolytic Virus Therapy Market Research Report with Forecast 2026 to 2035
Share With :
Gloabal Oncolytic Virus Therapy Market Size is valued at USD 17.35 Million in 2025 and is predicted to reach USD 157.20 Million by the year 2035 at a 25.6% CAGR during the forecast period for 2026 to 2035.
Oncolytic Virus Therapy Market Size, Share & Trends Analysis Report By Product (Herpes Simplex Virus (HSV), Adenoviruses, Vaccinia Virus, Vesicular Stomatitis Virus, Newcastle Disease Virus), By Application, By Region, And By Segment Forecasts, 2026 to 2035.
In recent decades, the healthcare burden of Cancer increasing rapidly with an increasing incidence rate. The massive investment in research and development has been implemented to find innovative drugs/therapy/Immuno oncology solutions to cure cancer. Some of them gaining interest include oncolytic viruses therapy, stem cell therapies, adoptive cell therapies, etc. Treatment-related off-target effects, side effects, and drug resistance hamper the efficacies of many therapeutic options. Therefore, scientists are working to develop new, effective therapies with low or no toxicity in normal cells. Oncolytic viruses therapy has shown immense opportunities and potential to be tapped in the future to enhance the cancer treatment. Immunotherapy with oncolytic viruses would definitely build survival solutions with significant importance.
The global oncolytic viruses therapy market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Adenoviruses, Herpes Simplex Virus, Vesicular Stomatitis Virus, Vaccinia Virus, and Newcastle Disease Virus. On the basis of application type, the market is segmented into Breast Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, and Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the oncolytic viruses therapy market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the oncolytic viruses therapy market during the analysis of the forecast period.
| Report Attribute | Specifications |
|
Market Size Value In 2025 |
USD 17.35 Million |
| Revenue Forecast In 2035 | USD 157.20 Million |
| Growth Rate CAGR | CAGR of 25.6% from 2026 to 2035 |
| Quantitative Units | Representation of revenue in US$ Million and CAGR from 2026 to 2035 |
| Historic Year | 2022 to 2025 |
| Forecast Year | 2026-2035 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | By Product, By Application |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; South Korea; South East Asia |
| Competitive Landscape | Provectus Biopharmaceuticals, Inc., Takara Bio Inc., SillaJen, Inc., Oncorus, Inc., Amgen, OncoMyx Therapeutics, Inc., Replimune Inc., Oncolytics Biotech, Vyriad, Inc., Viralytics, Transgene SA, OncolysBioPharma, Unleash ImmunoOncolytics, Inc., TargovaxPsiOxus Therapeutics, Sorrento Therapeutics, Lokon Pharma AB, Genelux Corporation, TILT Biotherapeutics, Cold Genesys and Western Oncolytics. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.